Bentsur Ron's Form 4 filing
Nuvectis Pharma, Inc. (NVCT) · filed Feb 8, 2022
- Accession no.
- 0001104659-22-013142
- Filed
- Feb 8, 2022
- Trade date
- Feb 4-7, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market purchases total $1.15M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bentsur RonCIK 0001251213 | Director, Officer (Chairman & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 4, 2022 | Common Stock, par value $0.00001 | PPurchaseAcquired | +200,000 | $5.00F1 | +$1,000,000 | 2,765,459 | Direct | |
| Feb 4, 2022 | Common Stock, par value $0.00001 | PPurchaseAcquired | +12,500 | $3.89F3 | +$48,625 | 2,777,959 | Direct | |
| Feb 7, 2022 | Common Stock, par value $0.00001 | PPurchaseAcquired | +14,000 | $3.93F4 | +$55,020 | 2,791,959 | Direct | |
| Feb 7, 2022 | Common Stock, par value $0.00001 | PPurchaseAcquired | +6,000 | $8.25 | +$49,500 | 2,797,959 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects the price of shares of common stock purchased by Mr. Bentsur in Nuvectis Pharma's initial public offering.
Referenced by the price of 1 transaction in Table I.
- F3
Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.83 to $3.95. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.60 to $4.25. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.